The effect of erectile dysfunction on quality of life following treatment for localized prostate cancer

Reviews in urology 02/2001; 3(3):113-9.
Source: PubMed


All forms of prostate cancer therapy carry significant risk of erectile dysfunction, but patients value sexual function so highly that they are often willing to choose a therapy that offers a shorter life expectancy but better potency following treatment. Advances in research methodology now allow reliable collection of meaningful data regarding patients' health-related quality of life, including both objective evaluation of patients' functional status and their perceptions of their own health and its impact on their existence. In the past decade, several validated and reliable questionnaires have been developed that are specifically designed to measure HRQOL in men with prostate cancer. Studies using these instruments have found that function and perceived bother may not be correlated; patients may express satisfaction with their therapy despite loss of sexual function. Erectile aids, including sildenafil, can be helpful for patients following treatment for localized prostate cancer.

3 Reads
  • Source
    • "Meyer et al (2003) determined that 72% of men (n 5 89) believed that QoL was moderately to severely affected, at a median of 92 months postoperatively , mainly because of persistent ED. The impact of ED on QoL is often significant, and many patients experience sexual bother as a result of post-RP ED; however, it is variable and individualized as to the degree that lack of sexual function correlates with sexual bother (Bates et al, 1998, Penson, 2001). However, multiple studies have demonstrated that QoL and sexual satisfaction improve with treatment of post-RP ED (Perez et al, 1997; Ramsawh et al, 2005; Albaugh and Ferrans, 2010). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Prostate cancer is the most common cancer in men and the second leading cause of cancer death. A favored treatment option for organ confined prostate cancer in a middle aged healthy man is radical prostatectomy (RP). Despite advances in techniques for RP, there remain concerns among physicians and patients alike on its adverse effects on sexual function. While post-RP erectile dysfunction (ED) has been extensively studied, little attention has been focused on the other domains of sexual function, namely loss of libido, ejaculatory dysfunction, orgasmic dysfunction, penile shortening, and Peyronie's disease. The aim of this review is to discuss the most recent literature regarding the post-RP sexual dysfunctions.
    Journal of Andrology 06/2012; 33(6). DOI:10.2164/jandrol.112.016790 · 2.47 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Critics of screening have stated that early detection of prostate cancer does not necessarily reflect a diminishing death rate from the disease. However, several recent reports have demonstrated that the death rate from prostate cancer is decreasing, representing the most compelling validation for aggressive screening. Prostate cancer can be halted only if there is no evidence of systemic or regional metastases and the disease is confined to the surgical field or the radiation template. Surgeons and radiation oncologists must make a concerted effort to exclude men with regional and systemic metastases who are unlikely to benefit from treatment. With the widespread acceptance of prostate-specific antigen screening, a greater proportion of men are being diagnosed with clinically localized prostate cancer. Both radical prostatectomy and radiation therapy are able to halt disease spread in this significant subset of men, but survival outcomes indicate that radical prostatectomy is a more reliable treatment than radiation therapy for clinically localized prostate cancer. Overall, the immediate treatment-related morbidity of radical prostatectomy and radiation therapy in the modern era is quite low. Radical prostatectomy and radiation therapy appear to have a similar impact on continence and erectile function. There is a need for neoadjuvant and adjuvant therapies that can be utilized in those cases where radical prostatectomy and radiation are less likely to completely eradicate or destroy the cancer.
    Reviews in urology 02/2004; 6 Suppl 2:S3-S12. DOI:10.1017/S0266462300000398
  • Source

    BJU International 08/2004; 94(2):238-43. DOI:10.1111/j.1464-410X.2004.04950.x · 3.53 Impact Factor
Show more

Similar Publications


3 Reads
Available from